Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We show that compound 5 exhibits good brain exposure and potent 2-HG inhibition in a HT1080-derived mouse xenograft model, which makes it a potential preclinical candidate to treat IDH1-mutant brain tumors.
|
31561044 |
2019 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Metrics used for this range from quantification of single oncometabolites (such as 2-hydroxyglutarate in mutant IDH1 glial brain tumours) to selected metabolite ratios (such as total choline to N-acetylaspartate (plain ratio or CNI index)) or the whole <sup>1</sup> H MRSI(I) pattern through pattern recognition analysis.
|
30633389 |
2019 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Arch Pathol Lab Med 138:241-256, 2014) in addition to serving as surrogate markers for molecular alterations in neoplasms, including IDH1 and ATRX mutations in brain tumors (Appin CL, Brat DJ.Mol Aspects Med.45:87-96, 2015).
|
30539453 |
2019 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We first demonstrated identical IDH mutations in the brain tumor samples from various locations in this patient, but different 1p,19q results by fluorescent in-situ hybridization, different whole genome copy number profiles by OncoScan analysis, and a discrepant IDH2M131I mutation unique to one tumor, supporting a multifocal disease process in the setting of somatic IDH mosaicism.
|
30159860 |
2018 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified in a number of cancer types, including brain cancer.
|
29849122 |
2018 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Isocitrate Dehydrogenase-1 (<i>IDH1)</i> is a driver gene in several cancers including brain tumors such as low-grade and high-grade gliomas.
|
29971034 |
2018 |
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Patients with wild-type IDH1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH1 tumors and no podoplanin expression (6-month risk 18.2% vs. 0%).
|
29676036 |
2018 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Exon 4 of IDH1 and IDH2 was analyzed in a series of brain tumors classified according to current WHO criteria.
|
29535392 |
2018 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Other than brain tumor or hematologic malignancies, intrahepatic cholangiocarcinoma (iCC) is a well-known solid tumor with IDH1 mutation (6.8-20%).
|
28403884 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The aim of this study is to investigate in depth the prevalence of non-R132H IDH ("non-canonical") mutations in brain tumors classified according to the 2016 WHO scheme and their clonal distribution in neoplastic cells.
|
28748342 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Genetic alterations of IDH1 and Vegf in brain tumors.
|
28948065 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.
|
28148827 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We show that a conformation-specific Fab can reactivate an IDH1 mutant associated with brain tumors.
|
28373671 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss.
|
28640702 |
2017 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1).
|
27820599 |
2016 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquisition scheme that uses an ultrahigh magnetic field (≥ 7T) capable of noninvasively detecting 2-HG with quantitative measurements sufficient to differentiate mutant cytosolic IDH1 and mitochondrial IDH2 in human brain tumors.
|
26669865 |
2016 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors.
|
27655638 |
2016 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The intraoperative assessment of IDH1 mutation is useful in brain tumor surgeries.
|
26695622 |
2016 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our findings indicate that CDKN2A/B risk genotypes are associated with primary glioblastoma without IDH mutation, and that there is an inverse association between RTEL1 risk genotypes and 1p/19q codeletion, suggesting that these genetic variants have a molecular impact on the genesis of high graded brain tumors.
|
26839018 |
2016 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Together, these findings (1) show that IDH mutation status is associated with a distinct angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging and (2) highlight the potential future of radiogenomics (i.e. the correlation between cancer imaging and genomic features) towards a more accurate diagnostic workup of brain tumors.
|
26538165 |
2015 |
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used human glioma tissues and derived brain tumor stem cells (BTSCs) to study the expression of HIF1α target genes in IDH mutant ((mt)) and IDH wild-type ((wt)) tumors.
|
24366912 |
2014 |
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
|
23558169 |
2013 |